Cohbar Inc Stock Price, News & Analysis

CohBar, Inc. (NASDAQ: CWBR) announced the appointment of Carol Nast as an independent director on its Board, effective August 11, 2021. With extensive experience in executive roles within the medical industry, Nast brings valuable commercial and operational expertise. Her appointment coincides with the positive topline data release from the CB4211 clinical study, focusing on mitochondria-based therapeutics. CohBar is advancing in its research with a diverse pipeline addressing chronic diseases, including its lead compound CB4211 for NASH and obesity.

CohBar, Inc. (NASDAQ: CWBR) reported its Q2 2021 financial results, highlighting positive topline data from its Phase 1a/1b trial of CB4211, aimed at treating NASH and obesity. The study met primary endpoints with no serious adverse events and showed significant improvements in liver biomarkers and glucose levels. However, cash reserves decreased to $13.8 million from $21 million at the end of 2020, with a net loss of $5.2 million. R&D and G&A expenses increased, raising concerns about future financial sustainability.

CohBar, Inc. (NASDAQ: CWBR) announced the topline results from its Phase 1a/1b clinical study of CB4211 for nonalcoholic steatohepatitis (NASH) and obesity. The study reported that CB4211 was well-tolerated with no serious adverse events. Key findings showed a significant reduction in liver enzymes ALT by 21% and AST by 28%, alongside a decrease in glucose levels. Additionally, there was a trend towards reduced body weight. The company plans to explore next steps for CB4211 based on these promising results, which may indicate potential for liver health improvements in NASH patients.

CohBar, Inc. (NASDAQ: CWBR) will release its second quarter 2021 financial results on August 10, 2021, after market close. A conference call with a slide presentation will follow at 5:00 p.m. ET. The company focuses on developing mitochondria-based therapeutics for chronic diseases. Its lead compound, CB4211, has completed a Phase 1a/1b clinical trial for NASH and obesity, while four preclinical programs are in progress, including CB5138-3 for idiopathic pulmonary fibrosis.

CohBar, Inc. (NASDAQ: CWBR) provides an update on its Phase 1a/1b clinical study of CB4211, targeted at treating nonalcoholic steatohepatitis (NASH) and obesity. Data entry and validation are ongoing, with topline results expected before Labor Day 2021. CB4211, a first-in-class mitochondria-based therapeutic, shows promise in preclinical models and addresses a significant health issue, as NASH affects approximately 30 million adults in the U.S. Importantly, there is no approved treatment for this condition.

CohBar, a clinical stage biotechnology company, announced that CEO Dr. Joseph Sarret will present an overview at the BIO 2021 Digital Conference, from June 14 to 18, 2021. This event, the largest of its kind, gathers biotechnology entities globally. CohBar focuses on developing mitochondria-based therapeutics targeting chronic diseases and aging-related issues. Their lead compound, CB4211, is currently in Phase 1b clinical trials for NASH and obesity, alongside four preclinical programs addressing various diseases.

CohBar, Inc. (NASDAQ: CWBR) reported Q1 2021 financial results with a net loss of $4 million, or $0.07 per share. Cash and investments stood at $17.8 million, down from $21 million at year-end 2020, reflecting a cash burn of approximately $4.2 million. The company is advancing its clinical programs, including CB4211 for NASH and obesity, with topline data expected in July 2021. Additionally, CohBar initiated IND-enabling studies for CB5138-3 aimed at fibrotic diseases. The firm appointed Dr. Joseph Sarret as CEO and gained research coverage from Aegis Capital and Maxim Group.

CohBar, Inc. (NASDAQ: CWBR) announced plans to release its first quarter 2021 financial results after market close on May 17, 2021. The company will host a conference call and slide presentation at 5:00 p.m. ET on the same day to discuss the results and provide a business update. Participants can join the call via specific dial-in numbers provided in the PR. Notably, CohBar focuses on developing mitochondria-based therapeutics for chronic diseases, with its lead compound, CB4211, currently in a Phase 1b clinical trial for NASH and obesity.

CohBar, Inc. (NASDAQ: CWBR) announced the appointment of Joseph J. Sarret, M.D., J.D. as its new CEO and Director, effective May 3, 2021. Sarret succeeds Steven Engle, who has contributed significantly during his tenure. David Greenwood is now the Chairman of the Board. Sarret brings extensive experience from prior roles, including Chief Business Officer at Corium International, and aims to advance CohBar's pipeline of mitochondria-based therapeutics, which includes its lead compound, CB4211, currently in Phase 1b clinical trials for NASH and obesity.